journal
https://read.qxmd.com/read/38511392/current-drug-strategies-for-the-treatment-and-control-of-schistosomiasis
#21
REVIEW
Maria Villamizar-Monsalve, Julio López-Abán, Belén Vicente, Rafael Peláez, Antonio Muro
INTRODUCTION: Schistosomiasis, one of the current Neglected Tropical Diseases (NTDs) affects over 230 million people globally, with nearly 700 million at risk in more than 74 countries. Praziquantel (PZQ) has served as the primary treatment for the past four decades; however, its effectiveness is limited as it solely eliminates adult worms. In regions where infections are frequent, PZQ exhibits only temporary efficacy and has restricted potential to disrupt the prolonged transmission of the disease...
March 21, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38497368/the-pharmacological-management-of-asthma-in-adults-2023-update
#22
REVIEW
Maria Gabriella Matera, Barbara Rinaldi, Rosa Annibale, Vito De Novellis, Mario Cazzola
INTRODUCTION: The pharmacotherapy of asthma is a dynamic process that changes as our knowledge of the underlying pathophysiology and treatment of this disease continues to evolve. This implies the need for continuous revision of the recommendations of asthma guidelines and strategies. AREAS COVERED: This review summarizes the latest key practical information on the pharmacological management of asthma in adults. We provide the background to the 2023 update of the GINA strategy report, focusing on changes and discussing areas of uncertainty...
March 20, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38503547/selinexor-in-multiple-myeloma
#23
REVIEW
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Annamaria Zimbo, Federica Torricelli, Antonino Neri, Fortunato Morabito, Massimo Gentile
INTRODUCTION: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM). AREAS COVERED: This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile. Clinical trials, such as STORM and BOSTON, have demonstrated its efficacy, particularly in combination regimens, showcasing notable overall response rates (ORR) and prolonged median progression-free survival (mPFS)...
March 19, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38497379/an-evaluation-of-rezafungin-the-latest-treatment-option-for-adults-with-candidemia-and-invasive-candidiasis
#24
REVIEW
Divisha Sharma, Jose A Vazquez
INTRODUCTION: Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata and C. auris , along with limitations in available treatments, highlights the urgent need for novel, effective antifungal agents. AREAS COVERED: This review discusses the results of in vitro studies evaluating the spectrum and highlights the pharmacokinetic/pharmacodynamic properties...
March 18, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38393835/pharmacological-management-of-fragile-x-syndrome-a-systematic-review-and-narrative-summary-of-the-current-evidence
#25
REVIEW
Lance V Watkins, Seungyoun Moon, Lisa Burrows, Samuel Tromans, Julian Barwell, Rohit Shankar
INTRODUCTION: Fragile X syndrome (FXS) is the most common inherited cause of Intellectual Disability. There is a broad phenotype that includes deficits in cognition and behavioral changes, alongside physical characteristics. Phenotype depends upon the level of mutation in the FMR1 (fragile X messenger ribonucleoprotein 1) gene. The molecular understanding of the impact of the FMR1 gene mutation provides an opportunity to target treatment not only at symptoms but also on a molecular level...
March 18, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38488824/pharmacotherapeutic-advances-for-chronic-myelogenous-leukemia-beyond-tyrosine-kinase-inhibitors
#26
REVIEW
Alessandro Costa, Emilia Scalzulli, Ida Carmosino, Claudia Ielo, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia
INTRODUCTION: Despite the notable success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML), a subset of patients experiences resistance, or relapse after discontinuation. This challenge is attributed to the Ph+ leukemia stem cells (LSCs) pool not fully involved in the inhibition process due to the current therapeutic approach. AREAS COVERED: Current pharmacological advancements in CML therapy focus on targeting LSCs, intervening in self-renewal pathways, and exploiting biological vulnerabilities...
March 15, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38465894/long-acting-second-generation-injectable-antipsychotics-for-the-maintenance-treatment-of-bipolar-disorder-a-narrative-review
#27
REVIEW
Jean-Baptiste Belge, Bernard G C C Sabbe
INTRODUCTION: Non-adherence to medication significantly affects bipolar disorder outcomes. Long-Acting Injectable antipsychotics show promise by ensuring adherence and averting relapses. AREAS COVERED: This narrative review sought to evaluate the efficacy of second-generation injectable antipsychotics in bipolar disorder through searches in Embase, MEDLINE, and PsycInfo for randomized controlled trials and mirror-image studies.Risperidone and aripiprazole Long-Acting Injectables demonstrated effectiveness in preventing mood recurrences compared to placebos in adults with bipolar disorder...
March 11, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38465524/therapeutic-strategies-in-fc%C3%AE-iia-receptor-dependent-thrombosis-and-thromboinflammation-as-seen-in-heparin-induced-thrombocytopenia-hit-and-vaccine-induced-immune-thrombocytopenia-and-thrombosis-vitt
#28
REVIEW
Luisa Müller, Venkata A S Dabbiru, Linda Schönborn, Andreas Greinacher
INTRODUCTION: Fcγ-receptors (FcγR) are membrane receptors expressed on a variety of immune cells, specialized in recognition of the Fc part of immunoglobulin G (IgG) antibodies. FcγRIIA-dependent platelet activation in platelet factor 4 (PF4) antibody related disorders have gained major attention, when these antibodies were identified as the cause of the adverse vaccination event termed vaccine-induced immune thrombocytopenia and thrombosis (VITT) during the Covid-19 vaccination campaign...
March 11, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38465412/novel-pharmacotherapeutic-options-for-the-treatment-of-postural-orthostatic-tachycardia-syndrome
#29
REVIEW
Anthony Lyonga Ngonge, Christabel Nyange, Jalal K Ghali
INTRODUCTION: Postural tachycardia syndrome (POTS) is a disorder characterized by a constellation of symptoms including lightheadedness, fatigue, and palpitations when upright, associated with an increase in the heart rate (HR) of > 30 beats per minute when changing from a lying down to standing position or head-up tilt position and not associated with orthostatic hypotension. The causes as well as the management of POTS are not quite fully understood. AREAS COVERED: We performed a literature review on the diagnosis and management of POTS, and this article includes an overview of novel pharmacotherapeutic options for the treatment of (POTS), although an effective treatment has not been established...
March 11, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38458647/glp-1-receptor-agonists-in-the-treatment-of-diabetic-non-alcoholic-steatohepatitis-patients
#30
JOURNAL ARTICLE
Ernest A Adeghate
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease affecting almost 30% of the world population. Approximately 25% of people with NAFLD develop nonalcoholic steatohepatitis (NASH), the fulminant version of the disease. Diabetes mellitus is present in 22.5% of people with NAFLD and 44.60% of individuals with NASH. This review was undertaken to examine the current contribution of glucagon-like peptide 1 (GLP-1) receptor agonists to the pharmacotherapy of diabetic nonalcoholic steatohepatitis...
March 8, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38436619/pharmacological-management-of-invasive-mold-infections-in-solid-organ-transplant-recipients
#31
REVIEW
Mario Fernández-Ruiz
INTRODUCTION: Solid organ transplant (SOT) recipients face an increased susceptibility to invasive fungal infection (IFI) due to filamentous fungi. Post-transplant invasive aspergillosis (IA) and mucormycosis are related to exceedingly high mortality rates and graft loss risk, and its management involve a unique range of clinical challenges. AREAS COVERED: First, the current treatment recommendations for IA and mucormycosis in SOT recipients are critically reviewed, including the supporting evidence...
March 4, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38407201/bp-lowering-effects-of-sglt-2-inhibitors-and-finerenone-an-indirect-comparison-in-patients-with-chronic-kidney-disease-and-type-2-diabetes
#32
EDITORIAL
Panagiotis I Georgianos, Christodoula Kourtidou, Maria Divani, Vassilios Liakopoulos
No abstract text is available yet for this article.
February 26, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38393775/impact-of-bladder-cancer-family-history-on-the-prognosis-of-patients-with-non-muscle-invasive-bladder-cancer-treated-with-bacillus-calmette-guerin-bcg
#33
JOURNAL ARTICLE
Mohamad Abou Chakra, Igor Duquesne, Michael Peyromaure, Sarah L Mott, Mohamad Moussa, Michael A O'Donnell
BACKGROUND: To evaluate the impact of having first-degree relatives (FDR) with bladder cancer (BC) among non-muscle invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette - Guérin (BCG) on their oncological outcomes. METHODS: The National Phase II BCG/Interferon (IFN) trial database from 125 sites in the U.S.A. (1999-2001) and multi-institutional databases from France (FR) and Lebanon (LB) (2000-2021) were queried for NMIBC patients treated with BCG...
February 23, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38393345/simnotrelvir-as-a-potential-treatment-for-covid-19
#34
JOURNAL ARTICLE
Matthew W McCarthy
INTRODUCTION: Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). AREAS COVERED: On 18 January 2024, results of a double-blind, randomized, placebo-controlled trial of simnotrelvir as a treatment for mild-to moderate COVID-19-were published, indicating the drug, when given in combination with ritonavir, shortened the time to resolution of symptoms. EXPERT OPINION: Treatment options for most outpatients with mild-to-moderate COVID-19 are limited...
February 23, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38372051/an-update-on-the-current-and-emerging-pharmacotherapy-for-the-treatment-of-human-ascariasis
#35
REVIEW
Kam Lun Hon, Alexander K C Leung
INTRODUCTION: Globally, Ascaris lumbricoides is the commonest helminthic infection that affects people in underdeveloped countries and returning immigrants in industrialized nations. This article aims to provide latest updates on the epidemiology, clinical manifestations, and pharmacotherapy of ascariasis. AREAS COVERED: A PubMed search was conducted using Clinical Queries and the key terms 'human ascariasis' OR 'Ascaris lumbricoides.' Ascaris lumbricoides is highly endemic in tropical and subtropic regions and among returning immigrants in industrialized nations...
February 19, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38362773/patterns-of-corticosteroid-use-among-remdesivir-and-matched-patients-and-associated-clinical-outcomes-in-hospitalized-covid-19-patients
#36
JOURNAL ARTICLE
Ivan Papic, Petra Bistrovic, Tatjana Keres, Maja Ortner Hadziabdic, Marko Lucijanic
INTRODUCTION: We aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution. METHODS: We retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients. RESULTS: A total of 167 (10.7%) patients received none, 710 (45...
February 16, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38344806/parkinson-s-disease-psychosis-management-an-evidence-based-experience-informed-pragmatic-approach
#37
JOURNAL ARTICLE
Joseph H Friedman
INTRODUCTION: Psychotic symptoms in people with Parkinson's disease (PD) have attracted increasing. Recommendations on treating psychosis often fail to take into account what psychotic symptoms require treatment, which has been complicated by the increasing number of reports documenting the frequency of 'minor' hallucinations. AREAS COVERED: this article focuses both on the phenomenology of psychotic symptoms and their management. EXPERT OPINION: Understanding the nature and implications of the types of psychotic symptoms in PD is the key to proper treatment...
February 12, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38315101/efficacy-and-safety-of-low-dose-oral-minoxidil-in-the-management-of-androgenetic-alopecia
#38
REVIEW
Aditya K Gupta, Mesbah Talukder, Avner Shemer
INTRODUCTION: Treating alopecia can be challenging. The available treatments are topical minoxidil, low-dose oral minoxidil (LDOM), and 5-α reductase inhibitors like finasteride and dutasteride. Only topical minoxidil and finasteride 1 mg daily are FDA-approved, while the rest are used off-label. Recent research has suggested that oral minoxidil may be a safe and effective treatment for both female androgenetic alopecia (female AGA) and male androgenetic alopecia (male AGA)...
February 5, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38299476/treatment-of-obesity-with-medications-binding-the-glucagon-like-peptide-1-receptor-what-is-the-current-state-of-play
#39
JOURNAL ARTICLE
Carel Le Roux, Alvin Mondoh
INTRODUCTION: Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations. AREAS COVERED: Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment...
February 1, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38284365/effectively-addressing-cardiovascular-risk-in-people-with-metabolic-dysfunction-associated-fatty-liver-disease-not-yet-ready-for-prime-time
#40
EDITORIAL
Theocharis Koufakis, Djordje S Popovic, Christodoulos Papadopoulos, Olga Giouleme, Michael Doumas
No abstract text is available yet for this article.
January 29, 2024: Expert Opinion on Pharmacotherapy
journal
journal
34813
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.